## **MEDICAL DIAGNOSTIC LABORATORIES**

|   |           | Final          |  |  |  |                                     |  |  |  |
|---|-----------|----------------|--|--|--|-------------------------------------|--|--|--|
| MDL#: 1241419   | 96        | Test Result    | ts   |  | Patient information SSN  | <b>DOB:</b> 2/13/1979 (Age:43)      |  |  |  |
| Date Received:  | 6/23/2022 | Date           | Reported:  | 7/1/2022                                   | DOE, JANE  |                                     |  |  |  |
| CLINICAL INFOR  | MATION    |                |  | - 123 MAIN ROAD                            |  |                                     |  |  |  |
|   |           |                |  |  | APT 2B   |                                     |  |  |  |
| Test Type:  | 1301 - L  | iquid Pap Test |  |  | VINELAND, NJ 08360   |                                     |  |  |  |
|   |           |                |  |  | Home: (856) 500-5555   | Patient ID: 1234567                 |  |  |  |
| Site of Collection:   | Cerv/En   | d              |  |  | Ordering Physician/Lab:  | NPI: 1234567890                     |  |  |  |
| LMP Date:   | N/A       |                |  |  | DOE MEDICAL GROUP  |                                     |  |  |  |
| Date of Collection:   | 6/22/20   | 22             |  |  | MARY DOE, MD   |                                     |  |  |  |
| Clinical History  | N/A       |                |  |  | 321 FIRST AVENUE   |                                     |  |  |  |
| Clinical History:   |           |                |  |  | SUITE 123  |                                     |  |  |  |
| Previous Results:   | N/A       |                |  |  | VINELAND, NJ 08360   |                                     |  |  |  |
|   | PATHOL    | OGY RESU       | JLTS   | Tel: (856) 500-1234<br>Fax: (856) 500-3214 |  |                                     |  |  |  |
| SPECIMEN ADEQUA   |           |                |  |  |  | Case#: 22-G052108a                  |  |  |  |
|   |           |                | ORY FOR EVALUATION. ENDOCERVICAL AND/OR SQUAMOUS Case#. 22-50521054<br>TIC CELLS (ENDOCERVICAL COMPONENT) ARE EVIDENT.   |  |  |                                     |  |  |  |
|   |           |                | CELLABNORMALITY.   |  |  |                                     |  |  |  |
| INTERPRETATION / LOW GRADE  |           |                | SQUAMOUS INTRAEPITHELIAL LESION (LSIL)   |  |  |                                     |  |  |  |
| DIAGNOSIS: ALSO PRESENT ARE A FEW ATYPICAL CELLS WITH HIGHER NUCLEAR TO   |           |                |  |  |  |                                     |  |  |  |
| CYTOPLASMIC RATIO (ASC-H).  |           |                |  |  |  |                                     |  |  |  |
|   |           |                | linical management is suggested.   |  |  |                                     |  |  |  |
| Previous Accession(s): N/A1. 18-G148550a 10/3/2018A: Epithelial Cell Abnormality. Low grade squamous intraepithelial lesion (LSIL). |           |                |  |  |  |                                     |  |  |  |
| Marideth De Castro  |           |                | iagnosing cancer. How  | wever, because the Pap Te                  | g which is a highly effective test in<br>st is inherently prone to sample-quality<br>-negative sampling, physicians should |                                     |  |  |  |
| Marideth de Castro, CT (ASCP)<br>Cytologist   |           |                | utilize the test results in conjunction with other clinical best practices. This liquid-based<br>ThinPrep® pap test was screened with the assistance of the Hologic Duo image-guided<br>system. For more information please go to our website: www.mdlab.com/papsmear. |  |  | Jing-Jing Yang, M.D.<br>Pathologist |  |  |  |

## **MOLECULAR RESULTS**

| Date Collected Specimen |                                      | Source   | Normal   | Abnormal     | Reference/Units/Comments |  |
|-------------------------|--------------------------------------|--|----------|--------------|--------------------------|--|
| * 105                   |                                      | tis by Real-Time PCR (Refle<br>ance by Pyrosequencing) | x to     |              | Positive                 | A2058C mutation detected. Suggestive of macrolide resistance.  |
| 6/22/2022               | Verified 6/23/2022                   | Thin-Prep - 1  | Cerv/End |              |                          |  |
| * 167                   | -                                    | ae by Real-Time PCR (Refl<br>ce by Molecular Analysis) |          |              | Positive                 | ****Ceftriaxone/cefixime resistance<br>mutations not detected. |
| 6/22/2022               | Verified 6/23/2022                   | Thin-Prep - 1  | Cerv/End |              |                          |  |
| * 739                   | HPV Type-Detect 4.0<br>Subtypes Only | by Real Time PCR High Risl                             | k        | Not Detected |                          | Subtypes HPV: No subtypes detected.<br>See explanation below.  |
| 6/22/2022               | Verified 6/24/2022                   | Thin-Prep - 1  | Cerv/End |              |                          |  |

\*This test was developed and its performance characteristics determined by the laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary

Thin-Prep-1;739:HPV Type-Detect 4.0 by Real Time PCR High Risk Subtypes Only No HPV subtypes were detected. The following were tested: High Risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.

Thin-Prep-1;105:Chlamydia trachomatis by Real-Time PCR (Reflex to Azithromycin Resistance by Pyrosequencing)

The A2058C mutation within the 23S rRNA gene has been identified as one mechanism of macrolide resistance (Misyurina OY et al. Anti Microb Agents and Chemother. 2004).

A negative result does not rule out the possibility of resistance in all instances

Thin-Prep-1;167:Neisseria gonorrhoeae by Real-Time PCR (Reflex to Antibiotic Resistance by Molecular Analysis)
\*\*\*\*The specimen was tested for antibiotic resistance to Ceftriaxone and Cefixime. The PenA gene of Neisseria gonorrhea is analyzed for mosaicism and the following amino acid substitutions: 201->H, 202->A, 203->G, 204->E, Q230->K, A311->V, I312->M, V316->T/P, and A323->S.

A positive result is provided for bacteria, virus, parasites, and/or fungal species when PCR amplification (real-time PCR), sequence information (Pyrosequencing), and/or sequencing analysis occurs above cut- off levels established by the laboratory. Pertinent reference intervals for the tests reported above are available from the laboratory upon request

Page 1 of 1 Ver. 18.52

М View. Yes USPS Mail: None Yes

NGONN Fax: Yes Manual None No



MDL#: 12414196 46750 8/12/2022 OP Final